Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the maximum tolerated dose (MTD) of
CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or
refractory multiple myeloma.